Browse by Audience
MEMBER

Update Your Profile
Special Interest Groups (SIG)
Member Spotlights
IASP Connect
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Pain Researcher
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Curricula
Graduate Opportunities
Treatment and Education Resources
Events

PATIENT & CAREGIVER

Resources for Living with Pain
Topic Pages
Free Videos
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner
Make a Donation

I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Dupilumab Significantly Improves Sleep Outcomes in Adult Patients with Atopic Dermatitis: Results from Five Randomized Clinical Trials.

< BACK TO ARCHIVE


2020 Aug 12


J Eur Acad Dermatol Venereol


http://www.ncbi.nlm.nih.gov/pubmed/32789996?dopt=Abstract

Dupilumab Significantly Improves Sleep Outcomes in Adult Patients with Atopic Dermatitis: Results from Five Randomized Clinical Trials.

Authors

Dupilumab Significantly Improves Sleep Outcomes in Adult Patients with Atopic Dermatitis: Results from Five Randomized Clinical Trials.
Beck LA, Silverberg JI, Simpson EL, Yosipovitch G, Eckert L, Guillemin I, Chen Z, Ardeleanu M, Plaum S, Graham N, Ruddy M, Pirozzi G, Gadkari A
J Eur Acad Dermatol Venereol. 2020 Aug 12.
PMID: 32789996.

Abstract

Sleep disturbances are part of a symptom triad, along with itch and pain, that patients with atopic dermatitis (AD) report as being frequent and burdensome. The effects of dupilumab on sleep were evaluated in adults with chronic AD in 5 randomized, double-blind, placebo-controlled clinical trials (N=2632). The phase 2b (NCT01859988) and the two phase 3 SOLO trials (SOLO 1, NCT02277743; SOLO 2, NCT02277769) were 16-week studies of dupilumab monotherapy, the 16-week CAFÉ (NCT02755649) and the 52-week CHRONOS trials (NCT02260986) evaluated dupilumab with concomitant topical corticosteroids (TCS).
Read This Paper